Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Xerava (eravacycline) is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Eravacycline demonstrated clinical efficacy comparable to carbapenems for complicated intra-abdominal infections (cIAIs), with no significant differences in clinical cure rate or microbiological eradication observed.
• In patients with cIAI and baseline bacteremia, eravacycline showed a higher clinical response rate (87.5%) compared to carbapenems (77.0%), with similar microbiologic eradication rates between eravacycline (97.1%) and carbapenem comparators (97.2%).
• Eravacycline was identified as a preferred carbapenem-sparing option based on network meta-analysis rankings, offering a viable alternative for managing cIAIs while maintaining comparable effectiveness to other antibiotics.
• No significant differences in adverse events were observed between eravacycline and carbapenems. However, eravacycline was associated with significantly higher odds of total adverse events and nausea compared to carbapenems, with no significant differences in serious adverse events or discontinuations due to adverse events.
• Cefepime plus metronidazole had fewer discontinuations due to adverse events compared to eravacycline, meropenem, and ceftolozane/tazobactam plus metronidazole, while eravacycline had fewer discontinuations due to adverse events compared to tigecycline.
• There is no population types or subgroups information available in the reviewed studies.